CD79A and hepatocellular carcinoma: These findings indicate that IL-21R promotes the tumorigenesis of MASH-driven HCC by inducing immunosuppressive IgA+ B cells and disrupting the IL-21R regulatory axis may be beneficial for MASH-driven HCC therapy.